REMS Audits: Legal and Practical Challenges
This article was originally published in RPM Report
Executive Summary
Biopharma companies have been vociferous in their objections to FDA's proposal that they audit other sectors of the health care system to determine the success of REMS once drugs get into commercial distribution. Audits would clearly be a large undertaking for biopharma companies. But even if they cannot cut off FDA's interest in an added audit function, the complaints may lead to a positive outcome: getting FDA on the side of more efforts by biopharma companies to track data on their products.
You may also be interested in...
Flying Blind: Learning to Live Without Physician Prescribing Data
Physicians aren't happy about the prescribing information companies use to help develop sales and marketing activities, and they're doing something about it. Policies adopted by medical professionals--and legislation moving at the state level--threaten to cut off marketers' access to information about who prescribes their products. Pharma companies better prepare to adapt to new ways of tracking sales.
Entries Begin To Roll In For 2024 Industry Awards
Entries have now begun rolling in for the Global Generics & Biosimilars Awards, which returns to Milan this October, Free to enter and attend, the ceremony recognizes the top achievements across the generics, biosimilars and value added medicines industries.
‘I Would Love To Have All The Biologic Assets’ – Formycon’s Glombitza Sets Out Portfolio Approach
In the second part of an exclusive interview, Formycon CEO Stefan Glombitza talks to Generics Bulletin about key regulatory developments in Europe and the US, the firm’s portfolio selection strategy, and upcoming milestones on the horizon.